Shanghai Pharmaceuticals Unveils Three New Products with Canadian Regulatory Approvals

Stock News
07/30

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that three of its products, manufactured by its subsidiary Shanghai Zhonghua Pharmaceutical Co., Ltd., have received product licenses from Natural and Non-prescription Health Products Directorate (NNHPD) of Health Canada. The approved products include Longhu Qingliangyou Regular, Longhu Qingliangyou Ultra, and Longhu Gunzhu Fengyoujing Oil.

These three products are primarily indicated for the temporary relief of muscle and joint aches or discomfort. Shanghai Zhonghua Pharmaceutical Co., Ltd. submitted the product registration application to Natural and Non-prescription Health Products Directorate (NNHPD) of Health Canada in May 2026. As of the date of this announcement, the company has incurred registration costs of approximately RMB 49,500 for the marketing of these products in Canada.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10